Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Hdl Handle:
http://hdl.handle.net/10147/200270
Title:
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
Authors:
Marsh, E A; Hirst, C L; Llewelyn, J G; Cossburn, M D; Reilly, M M; Krishnan, A; Doran, M; Ryan, A M; Coles, A J; Jones, J L; Robertson, N P
Affiliation:
Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.
Citation:
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. 2010, 257 (6):913-9 J. Neurol.
Journal:
Journal of neurology
Issue Date:
Jun-2010
URI:
http://hdl.handle.net/10147/200270
DOI:
10.1007/s00415-009-5437-3
PubMed ID:
20049473
Abstract:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.
Item Type:
Article
Language:
en
Description:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.
MeSH:
Adolescent; Adult; Age of Onset; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Time Factors; Treatment Outcome; Young Adult
ISSN:
1432-1459

Full metadata record

DC FieldValue Language
dc.contributor.authorMarsh, E Aen
dc.contributor.authorHirst, C Len
dc.contributor.authorLlewelyn, J Gen
dc.contributor.authorCossburn, M Den
dc.contributor.authorReilly, M Men
dc.contributor.authorKrishnan, Aen
dc.contributor.authorDoran, Men
dc.contributor.authorRyan, A Men
dc.contributor.authorColes, A Jen
dc.contributor.authorJones, J Len
dc.contributor.authorRobertson, N Pen
dc.date.accessioned2012-01-05T13:55:32Z-
dc.date.available2012-01-05T13:55:32Z-
dc.date.issued2010-06-
dc.identifier.citationAlemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. 2010, 257 (6):913-9 J. Neurol.en
dc.identifier.issn1432-1459-
dc.identifier.pmid20049473-
dc.identifier.doi10.1007/s00415-009-5437-3-
dc.identifier.urihttp://hdl.handle.net/10147/200270-
dc.descriptionChronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.en
dc.description.abstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an idiopathic immune mediated neuropathy causing demyelination and conduction block thought to occur as the result of an aberrant autoimmune response resulting in peripheral nerve inflammation mediated by T cells and humoral factors. Diagnosis commonly prompts initial treatment with steroids or intravenous immunoglobulin (IVIG) on which 5-35% subsequently become dependent to maintain function. Despite a number of small scale trials, the role for alternative long-term immunosuppression remains unclear. Alemtuzumab is a humanised monoclonal antibody targeting the CD52 antigen present on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopoenia lasting >12 months. We report its use and clinical outcome in a small series of patients with severe IVIG-dependent CIDP. Seven patients (4 Males; 3 Females) who had failed to respond to conventional immunosuppression were treated in 5 centres receiving 9 courses of alemtuzumab (dose range 60-150 mg). Following treatment, mean monthly IVIG use fell 26% from 202 to 149 g and IVIG administration frequency from 22 to 136 days. Two patients had prolonged remission, two patients had a partial response and no clear benefit was observed in the remaining three patients (2 Males, 1 Females). Responding patients had a younger age at onset (19.5 years) and shorter disease duration than non-responders. Three patients developed autoimmune disease following treatment. Alemtuzumab may offer an alternative treatment for a subset of early onset IVIG dependent CIDP patients failing conventional immunosuppressive agents, but concerns about toxicity may limit its use.-
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAge of Onset-
dc.subject.meshAnemia, Hemolytic, Autoimmune-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntibodies, Monoclonal, Humanized-
dc.subject.meshAntibodies, Neoplasm-
dc.subject.meshChild-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulins, Intravenous-
dc.subject.meshImmunologic Factors-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPolyradiculoneuropathy, Chronic Inflammatory Demyelinating-
dc.subject.meshTime Factors-
dc.subject.meshTreatment Outcome-
dc.subject.meshYoung Adult-
dc.titleAlemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Neurology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.en
dc.identifier.journalJournal of neurologyen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.